The molecular mechanisms of immunomodulation and tolerance induction to factor VIII

Summary.  Successful factor (F) VIII replacement therapy in hemophilia A patients is confounded by the generation of inhibitory anti‐FVIII antibodies (Ab) in 25–30% of treated patients. These antibodies, termed ‘inhibitors’, significantly increase morbidity within the hemophilia population and lower the quality of life for these patients. For the past 30 years, immune tolerance induction (ITI) has been the standard therapy to elicit immunological tolerance to FVIII in the clinic. ITI works well in approximately 75% of patients, but it is expensive, can take years to show effect and is in many cases practically challenging. Therefore, new immunological tolerance induction strategies are now being designed and tested in hemophilia A animal models. This review attempts to provide a comprehensive description, at both the cellular and molecular levels, of these novel advances in tolerance induction and immunomodulation of FVIII. We begin by briefly reviewing why and how the immune system generates a protective response against exogenous FVIII. This leads to a discussion of the latest advances in FVIII tolerance/immunomodulation technology. These advances include interesting methodologies to induce B cell specific tolerance in FVIII primed humans and animals, as well as newer T cell‐specific therapies that modify and/or block co‐stimulation. We also discuss methods to manipulate FVIII loading of antigen‐presenting cells.

[1]  T. Lambert,et al.  Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. , 2006, Blood.

[2]  R. Ahmed,et al.  Humoral immunity due to long-lived plasma cells. , 1998, Immunity.

[3]  J. Cambier,et al.  FcγRIIB activation leads to inhibition of signalling by independently ligated receptors , 2001 .

[4]  S. Kaveri,et al.  Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A. , 2008, Blood.

[5]  J. Bluestone,et al.  CD3-specific antibodies: a portal to the treatment of autoimmunity , 2007, Nature Reviews Immunology.

[6]  D. Scott,et al.  Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins. , 2005, Blood.

[7]  A. Sharpe,et al.  Prevention and treatment of factor VIII inhibitors in murine hemophilia AJ. Qian, M. Collins, A.H. Sharpe, et al. Blood 95:1324–1329, 2000 , 2000 .

[8]  C. Hay,et al.  The international immune tolerance study: a multicenter prospective randomized trial in progress , 2006, Journal of thrombosis and haemostasis : JTH.

[9]  M. Reding.  Immunological aspects of inhibitor development , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[10]  R. Kaufman,et al.  The molecular basis for cross-reacting material-positive hemophilia A due to missense mutations within the A2-domain of factor VIII. , 1998, Blood.

[11]  L. Burkly,et al.  Role of CD154 in the secondary immune response: the reduction of pre‐existing splenic germinal centers and anti‐factor VIII inhibitor titer , 2000, European journal of immunology.

[12]  T. Kurosaki,et al.  The B Cell Inhibitory Fc Receptor Triggers Apoptosis by a Novel c-Abl Family Kinase-dependent Pathway* , 2005, Journal of Biological Chemistry.

[13]  L. Klein,et al.  Promiscuous gene expression in medullary thymic epithelial cells mirrors the peripheral self , 2001, Nature Immunology.

[14]  H. Kazazian,et al.  Inhibitor Antibody Development and T Cell Response to Human Factor VIII in Murine Hemophilia A , 1999, Thrombosis and Haemostasis.

[15]  M. de Maeyer,et al.  In vivo neutralization of a C2 domain-specific human anti-Factor VIII inhibitor by an anti-idiotypic antibody. , 2004, Blood.

[16]  K. Mann,et al.  Quantitation of anti-factor VIII antibodies in human plasma. , 2009, Blood.

[17]  M. Cragg,et al.  Mechanisms of killing by anti-CD20 monoclonal antibodies. , 2007, Molecular immunology.

[18]  S. Jameson,et al.  Central tolerance: learning self-control in the thymus , 2005, Nature Reviews Immunology.

[19]  T. Ohmori,et al.  Induction of factor VIII‐specific unresponsiveness by intrathymic factor VIII injection in murine hemophilia A , 2009, Journal of thrombosis and haemostasis : JTH.

[20]  M. Othman,et al.  Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice. , 2009, Blood.

[21]  G. Freeman,et al.  Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice. , 2008, Blood.

[22]  D. Scott,et al.  Mechanisms of Gene Therapy for Tolerance: B7 Signaling Is Required for Peptide-IgG Gene-Transferred Tolerance Induction1 , 2005, The Journal of Immunology.

[23]  M. Pescovitz.  Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action , 2006, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[24]  H. Schwarz,et al.  Recombinant factor VIII and factor VIII-von Willebrand factor complex do not present danger signals for human dendritic cells , 2006, Thrombosis and Haemostasis.

[25]  K. Herold,et al.  Treatment of type 1 diabetes with anti-CD3 monoclonal antibody , 2003, Immunologic research.

[26]  G. Lippi,et al.  Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients’ analysis , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[27]  P. Mannucci,et al.  Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma‐product exposed toddlers) , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[28]  S. Kaveri,et al.  A Cellular Viewpoint of Anti-FVIII Immune Response in Hemophilia A , 2009, Clinical reviews in allergy & immunology.

[29]  D. DiMichele,et al.  Immune tolerance therapy for factor VIII inhibitors: moving from empiricism to an evidence‐based approach , 2007, Journal of thrombosis and haemostasis : JTH.

[30]  T. Lebien,et al.  B lymphocytes: how they develop and function. , 2008, Blood.

[31]  D. Scandella,et al.  Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A. , 2001, Blood.

[32]  H. Schwarz,et al.  Blockade of CD40/CD40 Ligand Interactions Prevents Induction of Factor VIII Inhibitors in Hemophilic Mice but Does not Induce Lasting Immune Tolerance , 2001, Thrombosis and Haemostasis.

[33]  S. Darby,et al.  The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99 , 2004, Journal of thrombosis and haemostasis : JTH.

[34]  S. Kaveri,et al.  VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. , 2007, Blood.

[35]  H. Wu,et al.  Mechanism of the Immune Response to Human Factor VIII in Murine Hemophilia A , 2001, Thrombosis and Haemostasis.

[36]  C. Mah,et al.  Indoleamine 2,3-dioxygenase attenuates inhibitor development in gene-therapy-treated hemophilia A mice , 2009, Gene Therapy.

[37]  H. Spencer,et al.  Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens. , 2007, Blood.

[38]  H. Oberg,et al.  Regulation of regulatory T cells: role of dendritic cells and toll-like receptors. , 2006, Critical reviews in immunology.

[39]  G. Auerswald,et al.  Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. , 2007, Blood.

[40]  D. Scott,et al.  Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". , 2008, Blood.

[41]  Scott N. Mueller,et al.  High antigen levels are the cause of T cell exhaustion during chronic viral infection , 2009, Proceedings of the National Academy of Sciences.

[42]  Michel Goldman,et al.  Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. , 2005, The New England journal of medicine.

[43]  Li Wu,et al.  The impact of circulating dendritic cells on the development and differentiation of thymocytes , 2009, Immunology and cell biology.

[44]  H. Weiner,et al.  Induction of partial immune tolerance to factor VIII through prior mucosal exposure to the factor VIII C2 domain , 2006, Journal of thrombosis and haemostasis : JTH.

[45]  J. Vermylen,et al.  Neutralizing antiidiotypic antibodies to factor VIII inhibitors after desensitization in patients with hemophilia A. , 1996, The Journal of clinical investigation.

[46]  A. Mowat,et al.  Anatomical basis of tolerance and immunity to intestinal antigens , 2003, Nature Reviews Immunology.

[47]  U. Dietrich,et al.  Humoral immune responsiveness to a defined epitope on factor VIII before and after B cell ablation with rituximab. , 2008, Molecular immunology.

[48]  S. Arkin,et al.  Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. , 1993, The New England journal of medicine.

[49]  H. Schwarz,et al.  Single Cell Analysis of Factor VIII-specific T Cells in Hemophilic Mice after Treatment with Human Factor VIII , 2002, Thrombosis and Haemostasis.

[50]  D. Scott,et al.  B Cells Induce Tolerance by Presenting Endogenous Peptide-IgG on MHC Class II Molecules via an IFN-γ-Inducible Lysosomal Thiol Reductase-Dependent Pathway1 , 2008, The Journal of Immunology.

[51]  Andreas Radbruch,et al.  Maintenance of serum antibody levels. , 2005, Annual review of immunology.

[52]  J. V. van Mourik,et al.  Tissue Distribution of Factor VIII Gene Expression In Vivo – A Closer Look , 2001, Thrombosis and Haemostasis.

[53]  J. Cambier,et al.  Fc gamma RIIB activation leads to inhibition of signalling by independently ligated receptors. , 2003, Biochemical Society transactions.

[54]  H. Schwarz,et al.  Characterization of Antibodies Induced by Human Factor VIII in a Murine Knockout Model of Hemophilia A , 2000, Thrombosis and Haemostasis.

[55]  Don C. Wiley,et al.  Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide , 1994, Nature.

[56]  P. Marrack,et al.  CD4 memory T cells divide poorly in response to antigen because of their cytokine profile , 2008, Proceedings of the National Academy of Sciences.

[57]  P. Bousso,et al.  Real-time manipulation of T cell-dendritic cell interactions in vivo reveals the importance of prolonged contacts for CD4+ T cell activation. , 2007, Immunity.

[58]  P. Anton van der Merwe,et al.  The nature of molecular recognition by T cells , 2003, Nature Immunology.

[59]  D. Scott,et al.  Mechanisms of Tolerance Induction by a Gene-Transferred Peptide-IgG Fusion Protein Expressed in B Lineage Cells1 2 , 2000, The Journal of Immunology.

[60]  C. Hausl,et al.  High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors. , 2005, Blood.

[61]  T. Kurosaki,et al.  SHIP recruitment attenuates Fc gamma RIIB-induced B cell apoptosis. , 1999, Immunity.

[62]  T. Kurosaki,et al.  SHIP Recruitment Attenuates FcγRIIB-Induced B Cell Apoptosis , 1999 .

[63]  J. Oldenburg,et al.  Genetic risk factors for inhibitors to factors VIII and IX , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[64]  C. Hausl,et al.  Long-term Persistence of Anti-factor VIII Antibody-secreting Cells in Hemophilic Mice after Treatment with Human Factor VIII , 2002, Thrombosis and Haemostasis.

[65]  P. Lenting,et al.  Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. , 2008, Blood.

[66]  T. Maimets,et al.  von Willebrand factor and transforming growth factor-beta modulate immune response against coagulation factor VIII in FVIII-deficient mice. , 2007, Thrombosis research.

[67]  W. Kreuz,et al.  Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs , 1992, The Lancet.

[68]  J. Goedert,et al.  Loss of high‐responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: A report from the multi‐center hemophilia cohort study , 1993, American journal of hematology.

[69]  K. Ghosh,et al.  Immune Response to FVIII in Hemophilia A: An Overview of Risk Factors , 2009, Clinical reviews in allergy & immunology.

[70]  M. Ozelo,et al.  Reduction of the immune response to factor VIII mediated through tolerogenic factor VIII presentation by immature dendritic cells , 2008, Journal of thrombosis and haemostasis : JTH.

[71]  J. Dyson,et al.  Use of a non‐depleting anti‐CD4 antibody to modulate the immune response to coagulation factors VIII and IX , 2002, British journal of haematology.

[72]  P. Thompson,et al.  Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response. , 2009, Blood.

[73]  R. Colvin,et al.  Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand , 2000, Nature Medicine.

[74]  J. Ravetch,et al.  Fcgamma receptors: old friends and new family members. , 2006, Immunity.

[75]  S. Arkin,et al.  Recombinant Factor VIII for the Treatment of Previously Untreated Patients with Hemophilia A: Safety, Efficacy, and Development of Inhibitors , 1993 .

[76]  D. Dimichele,et al.  Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors. , 2000, Haematologica.

[77]  J. Ravetch,et al.  Fcgamma receptors: old friends and new family members. , 2006, Immunity.

[78]  C. Hausl,et al.  Preventing restimulation of memory B cells in hemophilia A: a potential new strategy for the treatment of antibody-dependent immune disorders. , 2004, Blood.

[79]  M. Lindorfer,et al.  Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis , 2007, Nature Clinical Practice Rheumatology.